Navigation Links
Biostar Pharmaceuticals, Inc. Receives the Chinese Military Drug Administration Clearance to Begin Clinical Trial for Zushima Analgesic Aerosol Spray
Date:10/7/2009

ence clinical trials, which is an important milestone to validate its efficacy. We anticipate Zushima will drive incremental revenue growth in 2010 and beyond," said Mr. Wang Ronghua, Chairman and CEO of Biostar Pharmaceuticals, Inc. "Developing new products with high revenue potential will continue to be a key component of our long-term strategy. We expect to immediately launch the Zushima spray in both military and civil markets after the final approval is received in 2010."

About Biostar Pharmaceuticals, Inc.

Biostar Pharmaceuticals, Inc., through its wholly-owned subsidiary in China, develops, manufactures and markets pharmaceutical and medical nutrient products for a variety of diseases and conditions. The Company's most popular product is its Xin Ao Xing Oleanolic Acid Capsule, an over-the-counter ("OTC") medicine for chronic hepatitis B, a disease affecting approximately 10% of the Chinese population. In addition to its hepatitis product, Biostar manufactures two broad-based OTC products, two prescription-based pharmaceuticals and ten nutrients. The Company has adopted international standards and is in the process of applying for two patents.

Safe Harbor

Certain statements in this release concerning our future growth prospects are forward-looking statements, within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended, which involve a number of risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding the success of our investments, risks and uncertainties regarding fluctuations in earnings, our ability to sustain our previous levels of profitability including on account of our ability to manage growth, intense compe
'/>"/>

SOURCE Biostar Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Biostar Pharmaceuticals, Inc. Receives Patent for Aoxing Ganbao
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
5. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
6. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
7. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
8. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
9. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
10. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
11. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... RALEIGH, N.C. , May 22, 2013 ... pleased to announce the launch of their web site ... reports [STEPh Reports].  About STEPh Reports ... drugs in development.  Each STEPh Report ... clinical trials data, projected launch year, company, and specific ...
(Date:5/22/2013)... N.J. , May 22, 2013 MEDIFIRST ... opportunity to update shareholders about some recent company developments. ... expand its avenues of communication with shareholders. Integrating social ... launched a Facebook page and will post updates on ... Twitter hashtag is #medifirstusa. Says CEO ...
(Date:5/22/2013)... , May 22, 2013 Ranbaxy ... Sankyo Co., Ltd. (hereafter, Daiichi Sankyo), announced on ... in recent years to address past conduct under ... Daiichi Sankyo continues to support ... the conduct of the past which led to ...
Breaking Medicine Technology:Scientific and Technical Evaluation of Pharmaceuticals, Inc. [STEPh, Inc.], Launches New Competitive Intelligence Web Site 2Medifirst Solutions, Inc. Announces Update To Shareholders 2
... dermatitis, the common, chronic, inflammatory skin disease marked by ... the past two decades and affects a disproportionate number ... to 20 percent of children in the United States ... dermatitis in the first few years of life. By ...
... Cash Position--Biologics License Application for Wrinkles/Nasolabial Folds Indication ... EXTON, Pa., March 5 Isolagen(TM), Inc. (Amex: ... efficacy results from a Phase II/III clinical study ... treatment of moderate to severe acne scars. The ...
Cached Medicine Technology:Emerging Therapies Could Help Ease The Chronic Symptoms of Atopic Dermatitis For Adults and Children 2Emerging Therapies Could Help Ease The Chronic Symptoms of Atopic Dermatitis For Adults and Children 3Emerging Therapies Could Help Ease The Chronic Symptoms of Atopic Dermatitis For Adults and Children 4Emerging Therapies Could Help Ease The Chronic Symptoms of Atopic Dermatitis For Adults and Children 5Isolagen, Inc. Reports Positive Top-line Results from Phase II/III Study of Isolagen Therapy(TM) to Treat Moderate to Severe Acne Scars: Study Meets All Primary Efficacy Endpoints and is Statistically Significant 2Isolagen, Inc. Reports Positive Top-line Results from Phase II/III Study of Isolagen Therapy(TM) to Treat Moderate to Severe Acne Scars: Study Meets All Primary Efficacy Endpoints and is Statistically Significant 3Isolagen, Inc. Reports Positive Top-line Results from Phase II/III Study of Isolagen Therapy(TM) to Treat Moderate to Severe Acne Scars: Study Meets All Primary Efficacy Endpoints and is Statistically Significant 4Isolagen, Inc. Reports Positive Top-line Results from Phase II/III Study of Isolagen Therapy(TM) to Treat Moderate to Severe Acne Scars: Study Meets All Primary Efficacy Endpoints and is Statistically Significant 5Isolagen, Inc. Reports Positive Top-line Results from Phase II/III Study of Isolagen Therapy(TM) to Treat Moderate to Severe Acne Scars: Study Meets All Primary Efficacy Endpoints and is Statistically Significant 6
(Date:5/22/2013)... study suggests that disturbed sleep in adolescents is ... uncertainly about future success. However, perceived support ... have a protective effect. , Results show ... mood and greater uncertainty about future success. Higher ... teachers were associated with significantly fewer sleep disruptions ...
(Date:5/22/2013)... the parents are married are less likely to be ... the University of Houston. , "Childhood obesity is a ... one-third of all U.S. children ages 2-17 overweight or ... sociology at Rice and director of Rice,s Kinder Institute ... been conducted to explore the impact of family structure ...
(Date:5/22/2013)... May 22, 2013 Slip and fall ... by a number of factors. A December 2010 CDC ... following hazards as the most common: contaminants on the ... weather conditions, inadequate lighting, and lack of handrails (i). ... bruises, strained ligaments and muscles, fractures, broken bones, ...
(Date:5/22/2013)... Monroe, OH (PRWEB) May 22, 2013 ... indoor air quality merchandise ranging from furnace filters, ... DiscountFurnaceFilters.com is excited to add Stadler Form's ... a fashionable summer product line (fans, aroma diffusers ... , Stadler Form’s Otto Fan is the perfect ...
(Date:5/22/2013)... Peak Solar introduces unique, interactive solar training seminars, ... customers make informed buying choices. Research studies tell companies ... is to give them the tools needed to make ... heart. Solar training seminars will be introduced onto the ... solar kits . , Poised to help both residential ...
Breaking Medicine News(10 mins):Health News:Parent and teacher support protects teens from sleep problems and depression 2Health News:Children of married parents less likely to be obese 2Health News:Children of married parents less likely to be obese 3Health News:Law Firm Releases Slip and Fall Accident Informational Graphic to Show the Frequency and Cost of These Incidents 2Health News:Law Firm Releases Slip and Fall Accident Informational Graphic to Show the Frequency and Cost of These Incidents 3Health News:DiscountFurnaceFilter.com Now Offers Stadler Form Products - Providing Solutions to All Your Summer Needs 2Health News:Online Solar Training Seminars Aimed at Informing Consumers 2
... consumer focused new and improved interface. The most highlighting feature of ... cyber consumers to choose and buy their niche medicines any time. ... ... USA,s most reliable online pharmacy, launched a brand new customer focused, ...
... Multiple customer agreements for Soarian Clinicals and Siemens ... for the system that streamlines the flow of ... 5 Siemens ( ... customer contracts and installations, along with strong existing-customer ...
... allergies, so be prepared, expert says , , SUNDAY, April ... child is one of the more than 35 million Americans ... the youngster enjoy being outside, one expert says. , ... with MCG Pediatric Primary Care Associates and MCGHealth Children,s Medical ...
... of a Post-Merger Integration and Restructuring Practice. The new practice ... posed by increasing financial pressures and the consolidating health care market. ... ... Health Strategies & Solutions, Inc. (HS&S), the nation,s leading health ...
... man that suffers from depression, erectile dysfunction, fatigue, poor concentration or hot ... is advising men ages 35 and over to have their hormone levels ... 4 out of 5 men age 40 have low testosterone, the leading ... ...
... Mass., April 4 Inverness Medical Innovations, Inc. (NYSE: ... individuals to take charge of their health at home ... announced today that it will attend the upcoming Goldman ... Wednesday, April 8, 2009 at the Goldman Sachs Conference ...
Cached Medicine News:Health News:Rxonlinetoday Launch Cyber Shop for FDA Approved Medicines 2Health News:Rxonlinetoday Launch Cyber Shop for FDA Approved Medicines 3Health News:Siemens Announces Latest Contracts, Recent 'Go Lives,' and Strong Customer Support for its Workflow-Enhancing Healthcare IT Solution Soarian Clinicals, at HIMSS 2009 2Health News:Siemens Announces Latest Contracts, Recent 'Go Lives,' and Strong Customer Support for its Workflow-Enhancing Healthcare IT Solution Soarian Clinicals, at HIMSS 2009 3Health News:Siemens Announces Latest Contracts, Recent 'Go Lives,' and Strong Customer Support for its Workflow-Enhancing Healthcare IT Solution Soarian Clinicals, at HIMSS 2009 4Health News:Breathe Easier Knowing Spring's Pollen Triggers 2Health News:The Nation's Leading Health Care Strategy Firm Launches Post-Merger Integration Practice 2Health News:The Nation's Leading Health Care Strategy Firm Launches Post-Merger Integration Practice 3Health News:Male Hormone Treatment Provider Announces Family Doctor Alert 2Health News:Male Hormone Treatment Provider Announces Family Doctor Alert 3Health News:Male Hormone Treatment Provider Announces Family Doctor Alert 4
... complete line of flowmeters, available in ... . They are all available in ... suit your application. With color coded ... gas in use, the Amvex Flowmeter ...
... Amvex offers a complete line ... heliox and CO 2 . They ... of calibrations to best suit your ... dials specific to the gas in ...
... line of flowmeters, available in oxygen, ... They are all available in a ... your application. With color coded labels ... in use, the Amvex Flowmeter is ...
... line of flowmeters, available in oxygen, air, heliox and ... variety of calibrations to best suit your application. With ... in use, the Amvex Flowmeter is a user friendly ... I. For Power Take-Off add PT to the end ...
Medicine Products: